Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for the treatment of advanced ovarian cancer (review of TA28, TA45 and TA55 (for relapsed disease only))
Summary
The guidance issued by NICE only applies to paclitaxel, PLDH and topotecan. NICE has issued the following recommendations for the treatment of women with advanced ovarian cancer:
Women for whom the cancer is:
The following treatments should be considered as options:
platinum-sensitiv ...
Read the complete summary
The guidance issued by NICE only applies to paclitaxel, PLDH and topotecan. NICE has issued the following recommendations for the treatment of women with advanced ovarian cancer:
|
Women for whom the cancer is: |
The following treatments should be considered as options: |
| platinum-sensitive or partially platinum-sensitive, except women who are allergic to platinum-based drugs |
paclitaxel in combination with a platinum-based drug (carboplatin or cisplatin) as an option for second-line (or subsequent) treatment |
| partially platinum-sensitive, platinum-resistant or platinum-refractory, and women who are allergic to platinum-based compounds |
PLDH as an option for second-line (or subsequent) treatment |
| platinum-refractory or platinum-resistant, and women who are allergic to platinum-based compounds |
paclitaxel on its own as an option for second-line (or subsequent) treatment |
| platinum-refractory or platinum-resistant, or women who are allergic to platinum-based compounds, for whom PLDH and single-agent paclitaxel are considered inappropriate. |
topotecan as an option for second-line (or subsequent) treatment. |
These recommendations also apply to ovarian cancer that relapses after second-line chemotherapy; this is called ‘subsequent’ chemotherapy.
Specialists should discuss the risks and benefits of each treatment option with patients before deciding which treatment to use for second-line (or subsequent) chemotherapy in line with the recommendations.
This guidance replaces TA28 Ovarian cancer - topotecan and TA45 Ovarian cancer (advanced) - pegylated liposomal doxorubicin hydrochloride.
hide
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in November 2009
